Skip to main content

Table 2 Objective response in the study population

From: A retrospective study of alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed

Variables, n (%)

Alectinib (n = 41)a

Ceritinib (n = 22)

Response

 No. of patients

30

11

 % (95% CI)

73.2 (57.1–85.8)

50.0 (28.2–71.8)#

Complete response-- no. (%)

1 (2.4)

0

Partial response--no. (%)

29 (70.8)

11 (50.0)

Stable disease--no. (%)

6 (14.6)

6 (27.3)

Progression disease--no. (%)

5 (12.2)

5 (22.7)

  1. aNot evaluable in 2 patients. # p = 0.096 for the comparison between alectinib and ceritinib
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us